Patents by Inventor Gabriele PSZOLLA

Gabriele PSZOLLA has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20210032370
    Abstract: The present invention concerns bispecific antigen binding proteins directed against MHC presented target antigens (TA). The invention in particular provides bispecific antigen binding proteins comprising at least two antigen binding sites (A and B), wherein the antigen binding site A binds to CD3 and the antigen binding site B binds to a target antigenic (TA) peptide/MHC complex. The bispecific antigen binding proteins of the invention comprise, in particular, the CDRs of the VL and VH domains of novel engineered anti-CD3 antibodies having a reduced affinity. The bispecific antigen binding proteins of the invention are of use for the diagnosis, treatment and prevention of TA associated diseases, such as tumor-associated antigen (TAA) expressing cancerous diseases.
    Type: Application
    Filed: July 30, 2020
    Publication date: February 4, 2021
    Inventors: Gabriele PSZOLLA, Martin HOFMANN, Felix UNVERDORBEN, Meike HUTT, Dominik MAURER, Sebastian BUNK
  • Publication number: 20210032361
    Abstract: The present invention concerns antigen binding proteins specifically binding melanoma associated antigen A (MAGE-A) protein-derived antigens. The invention in particular provides antigen binding proteins which specifically bind to the MAGE-A antigenic peptide comprising or consisting of SEQ ID NO: 1 in a complex with a major histocombatibility (MHC) protein. The antigen binding proteins of the invention contain, in particular, the complementary determining regions (CDRs) of novel engineered T cell receptors (TCRs) that specifically bind to said MAGE-A peptide/MHC complex. The antigen binding proteins of the invention are of use for the diagnosis, treatment and prevention of MAGE-A expressing cancerous diseases. Further provided are nucleic acids encoding the antigen binding proteins of the invention, vectors comprising these nucleic acids, recombinant cells expressing the antigen binding proteins and pharmaceutical compositions comprising the antigen binding proteins of the invention.
    Type: Application
    Filed: July 30, 2020
    Publication date: February 4, 2021
    Inventors: Meike HUTT, Felix UNVERDORBEN, Sebastian BUNK, Dominik MAURER, Martin HOFMANN, Gabriele PSZOLLA, Sara YOUSEF, Claudia WAGNER, Frank SCHWOEBEL, Heiko SCHUSTER
  • Patent number: 10665324
    Abstract: A method for constructing a library of amino-acid sequences having a common structural fold, and a method for designing and selecting an amino-acid sequence having a desired affinity to a molecular surface of interest of a molecular entity, using the library, are provided herein. The methods are based on a stochastic sampling of backbone conformations and amino acid conservation patterns observed in experimentally available protein structures having the common structural fold.
    Type: Grant
    Filed: July 6, 2015
    Date of Patent: May 26, 2020
    Assignee: Yeda Research and Development Co. Ltd.
    Inventors: Sarel Fleishman, Gideon Lapidoth, Maria Gabriele Pszolla, Christoffer Norn
  • Publication number: 20170206308
    Abstract: A method for constructing a library of amino-acid sequences having a common structural fold, and a method for designing and selecting an amino-acid sequence having a desired affinity to a molecular surface of interest of a molecular entity, using the library, are provided herein. The methods are based on a stochastic sampling of backbone conformations and amino acid conservation patterns observed in experimentally available protein structures having the common structural fold.
    Type: Application
    Filed: July 6, 2015
    Publication date: July 20, 2017
    Inventors: Sarel FLEISHMAN, Gideon LAPIDOTH, Maria Gabriele PSZOLLA, Christoffer NORN